查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018635

穿戴式人工腎臟市場：2026-2032年全球市場預測（依治療方法、技術、年齡層、最終用戶和通路分類）

Wearable Artificial Kidney Market by Therapy Type, Technology, Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，穿戴式人工腎臟市場價值將達到 2.512 億美元，到 2026 年將成長至 2.9996 億美元，到 2032 年將達到 8.8688 億美元，年複合成長率為 19.74%。

主要市場統計數據
基準年 2025 2.512億美元
預計年份：2026年 2.9996億美元
預測年份 2032 8.8688億美元
複合年成長率 (%) 19.74%

這是穿戴式人工腎臟技術創新的權威指南，系統地闡述了臨床優先事項、技術促進因素、監管期望以及相關人員合作，以促進其實施。

穿戴式人工腎臟技術融合了數十年的臨床需求、工程小型化以及以患者為中心的護理模式。末期腎病患者正在尋求能夠減少對醫療機構依賴、提高生活品質並增強自主性的替代方案。同時，膜材料、吸附劑化學、流體力學和低功耗電子技術的進步，為在傳統透析中心之外提供持續或間歇性移動腎臟支持奠定了切實可行的技術基礎。

技術小型化、分散式護理趨勢、監管協調以及對數位化整合的前瞻性分析正在重塑腎臟替代療法的提供方式。

腎臟替代療法領域正經歷著由技術、醫療服務模式和政策工具共同驅動的變革，這些變革正在重新定義慢性腎臟病管理的可能性。在技​​術層面，泵浦和感測器的微型化、利用吸附劑的透析化學技術的進步以及低功耗電子裝置的出現，降低了攜帶式解決方案的門檻，使得設備比以往的原型更輕、更安靜、更節能。

深入分析 2025 年美國關稅對穿戴式人工腎臟開發公司的設備供應鏈、籌資策略、製造在地化和市場定位的影響。

2025年美國關稅政策將對醫療設備供應鏈產生微妙的影響，尤其對穿戴式人工腎臟所需的高階電子機械元件和耗材而言更是如此。對進口設備子系統和原料徵收的關稅可能會增加依賴全球供應商的製造商的採購成本，而這種成本壓力反過來又會影響定價策略、採購決策以及生產能力的地理分佈。

詳細的基於細分市場的分析揭示了治療方法、醫療保健環境、分銷管道、使用模式和年齡層如何影響產品策略和商業化。

為了解市場，必須分析治療方法、醫療機構、分銷體系、技術使用模式和病患人口統計特徵，以確定臨床效益與商業性可行性的交集。血液透析和腹膜透析的治療方法不同，因此需要不同的技術和臨床方案。血液透析方案包括傳統系統和超攜帶式設備，後者專注於體外循環和吸附劑再生；而腹膜透析則包括自動化系統和持續移動療法，利用腹膜清除溶質。這些差異導致了獨特的設計限制、消毒方案和患者培訓需求。

從區域比較觀點全球不同市場的醫療保健基礎設施、報銷制度、監管多樣性和商業化路徑。

地理趨勢在各大區域間差異顯著，醫療基礎設施、支付系統和法規結構的差異影響腎臟疾病的研發和推廣路徑。在美洲，成熟的臨床網路和不斷發展的門診護理模式推動了對門診和居家腎臟解決方案的需求，這些解決方案注重整合式醫療服務和明確的報銷機制。該地區的醫療服務提供者通常優先考慮那些療效顯著、運作效率高且能夠整合到現有透析網路中的設備。

對塑造穿戴式人工腎臟產業領導地位的競爭動態、夥伴關係模式、智慧財產權重點和投資重點進行策略性總結。

競爭格局由傳統透析設備製造商、成熟的醫療設備公司以及專注於新型吸附劑化學、輕量化流體力學和整合感測技術的敏捷型Start-Ups組成。成熟企業擁有深厚的臨床關係、生產規模和完善的分銷網路，結合迭代式臨床檢驗，能夠加速新型醫療設備的市場准入。Start-Ups和衍生公司通常源自於大學工程或臨床研究團隊，它們更傾向於快速原型製作、以用戶為中心的設計以及非傳統的監管合規和報銷策略。

一系列可操作的策略，旨在透過臨床檢驗、供應鏈多元化、監管參與、擴大生產規模以及與支付方合作來加速推廣應用。

產業領導者應採取多管齊下的策略，平衡臨床檢驗、供應鏈韌性和商業化準備，以加速產品推廣應用並降低風險。優先進行以患者為中心的嚴謹臨床項目，這些項目應同時關注傳統終點和生活品質 (QOL) 指標。將病患報告結局 (PRO) 納入早期研究，有助於向支付者和醫療服務提供者傳遞價值訊息。同時，應儘早與監管機構合作，就可接受的安全性和有效性終點達成一致，並探索能夠簡化市場准入流程的適應性核准途徑。

我們將對用於得出見解的混合方法研究途徑進行透明的解釋，該方法結合了初步訪談、臨床文獻整合、監管審查、知識產權 (IP) 格局分析和供應鏈映射。

這些研究結果基於混合方法，該方法結合了對關鍵相關人員的訪談、臨床文獻整合、監管文件審查和供應鏈分析。主要研究包括對腎臟科醫生、生物醫學工程師、醫院採購經理和醫療設備研發主管的深入訪談，以了解實際運作和臨床方面的優先事項。此外，還透過對同行評審的臨床試驗、研究者主導的臨床試驗和醫療設備註冊數據的系統性回顧，補充了這些定性信息，以評估安全性訊號和療效終點。

一項權威的綜合分析強調了穿戴式腎臟解決方案廣泛應用的相互依存的要求：臨床檢驗、監管合規性、供應鏈韌性和相關人員價值。

穿戴式人工腎臟技術正處於臨床需求未被滿足、技術能力快速發展以及醫療服務模式不斷演變的關鍵交會點。其廣泛的臨床應用不僅取決於技術效能，還取決於嚴格的臨床檢驗、協調一致的監管策略、穩健的供應鏈以及清晰的報銷途徑。能夠成功整合以患者為中心的設計理念、可驗證的臨床結果以及營運擴充性的製造商，將最有能力影響醫療保健模式的變革。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的穿戴式人工腎臟市場

  • 血液透析
    • 傳統血液透析
    • 超攜帶式血液透析
  • 腹膜透析
    • 自動腹膜透析
    • 持續性移動腹膜透析

第9章 穿戴式人工腎臟市場：依技術分類

  • 持續穿著
    • 長期使用
    • 短時間內
  • 間歇性應用
    • 日常使用
    • 經常使用

第10章：穿戴式人工腎臟市場：依年齡層別分類

  • 成人版
  • 兒童

第11章 穿戴式人工腎臟市場：依最終用戶分類

  • 門診部
  • 居家照護
  • 醫院和診所

第12章 穿戴式人工腎臟市場：依通路分類

  • 線下銷售
    • 直銷
    • 銷售代理
  • 線上銷售

第13章 穿戴式人工腎臟市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 穿戴式人工腎臟市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 穿戴式人工腎臟市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國穿戴式人工腎臟市場

第17章：中國穿戴人工腎臟市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ANSELL LTD
  • Asahi Kasei Medical Co., Ltd.
  • Awak Technologies
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Cardinal Health
  • Dynarex Corporation
  • GE Healthcare
  • Hartalega Holdings
  • Hitachi Medical Corporation
  • KAWASUMI LABORATORIES, INC
  • Koninklijke Philips NV
  • Medline Industries, Inc
  • Nanodialysis BV
  • Siemens AG
  • Triomed AB
  • Wearable Artificial Organs Inc.
Product Code: MRR-221461476D86

The Wearable Artificial Kidney Market was valued at USD 251.20 million in 2025 and is projected to grow to USD 299.96 million in 2026, with a CAGR of 19.74%, reaching USD 886.88 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 251.20 million
Estimated Year [2026] USD 299.96 million
Forecast Year [2032] USD 886.88 million
CAGR (%) 19.74%

An authoritative orientation to wearable artificial kidney innovation that frames clinical priorities, technological enablers, regulatory expectations, and stakeholder alignment for adoption

Wearable artificial kidney technology represents a convergence of decades-long clinical need, engineering miniaturization, and patient-centered care models. Individuals with end-stage renal disease seek alternatives that reduce time tethered to clinical facilities, improve quality of life, and enable greater autonomy. Simultaneously, advances in membrane materials, sorbent chemistry, fluidics, and low-power electronics have created a feasible technological foundation for continuous or intermittent ambulatory renal support outside of traditional dialysis centers.

Clinical teams and device developers are now focused on balancing efficacy, safety, and usability. Early-stage clinical evaluations have emphasized hemodynamic stability, solute clearance, fluid management, and infection control as critical endpoints. Patient experience metrics, such as comfort during wear, ease of handling, and integration with daily activities, are emerging as equally important determinants of adoption. Payers and health systems are scrutinizing the evidence base required to justify new care pathways, seeking clear data on clinical outcomes, hospital utilization, and patient-reported benefits.

Given this context, the trajectory for wearable artificial kidney solutions is shaped by multidisciplinary collaboration among nephrologists, biomedical engineers, regulatory strategists, and supply chain specialists. The innovation imperative sits alongside a pragmatic demand for robust clinical validation and manufacturing pathways that meet the rigorous standards of medical device regulation and routine clinical use.

A forward-looking analysis of technological miniaturization, decentralized care trends, regulatory alignment, and digital integration reshaping renal replacement therapy delivery

The landscape for renal replacement therapies is undergoing transformative shifts driven by technology, care delivery models, and policy levers that together reconfigure what is possible for chronic kidney disease management. On the technology front, miniaturization of pumps and sensors, advances in sorbent-based dialysis chemistry, and low-power electronics have reduced barriers to ambulatory solutions, enabling devices that are lighter, quieter, and more energy efficient than previous prototypes.

Concurrently, care delivery is shifting toward decentralized models that favor home-based and community-integrated care. This trend reflects growing demand from patients for greater autonomy and from health systems for interventions that reduce inpatient utilization and rehospitalization. Regulatory frameworks have been adapting to accommodate novel device categories through iterative guidance and pathway optimization, encouraging early collaboration between developers and regulators to align clinical endpoints with safety expectations.

Digital health integration is another catalytic force; remote monitoring, cloud-based data aggregation, and predictive analytics allow clinicians to oversee therapy adherence and intervene proactively. These capabilities create new value propositions around continuity of care, personalized therapy adjustments, and longitudinal outcome tracking. Taken together, these shifts are aligning incentives across stakeholders and setting the stage for meaningful changes in how renal replacement therapies are developed, evaluated, and reimbursed.

A pragmatic exploration of how 2025 US tariffs affect device supply chains, sourcing strategies, manufacturing localization, and commercial positioning for wearable artificial kidney developers

The United States tariff landscape in 2025 introduces nuanced implications for the medical device supply chain, particularly for advanced electromechanical and consumable components integral to wearable artificial kidneys. Tariffs imposed on imported device subsystems or raw materials can increase landed costs for manufacturers that rely on global suppliers, and those cost pressures may in turn affect pricing strategies, sourcing decisions, and the geographic allocation of manufacturing capacity.

Beyond direct cost impacts, tariffs can create incentive structures for nearshoring and supplier diversification. Device developers and original equipment manufacturers may accelerate efforts to qualify domestic suppliers, invest in local assembly capabilities, or renegotiate long-term supplier agreements to mitigate exposure. These strategies can lengthen lead times in the near term but potentially strengthen supply chain resilience and reduce exposure to future trade policy volatility.

Regulatory and reimbursement stakeholders will be watching how tariff-driven cost dynamics interact with pricing negotiations and reimbursement policy. Health systems and payers may push for evidence that cost increases do not erode value propositions, prompting manufacturers to demonstrate clinical benefit and cost-effectiveness more rigorously. From a strategic perspective, manufacturers that proactively adapt supply chain architecture, invest in local manufacturing competencies, and communicate transparent cost and quality controls will be better positioned to navigate tariff-related disruption while preserving market access and stakeholder confidence.

A nuanced segmentation-driven synthesis revealing how therapy modalities, care settings, distribution channels, wear patterns, and age cohorts together inform product strategy and commercialization

Understanding the market requires parsing therapy modalities, settings of care, distribution frameworks, technological wear patterns, and patient demographics to identify where clinical benefit and commercial viability converge. Therapy modality distinctions between hemodialysis and peritoneal dialysis create divergent engineering and clinical pathways; hemodialysis approaches include conventional systems and ultraportable variants that emphasize extracorporeal circulation and sorbent regeneration, while peritoneal dialysis encompasses automated systems and continuous ambulatory modalities that leverage the peritoneal membrane for solute clearance. These differences translate into unique design constraints, sterilization protocols, and patient training needs.

End-user segmentation further refines deployment strategies. Ambulatory centers demand devices that integrate with existing clinical workflows and support throughput, home care adoption prioritizes simplicity, remote monitoring, and robust safety features, and hospital clinics require compatibility with institutional protocols and infection control standards. The choice of distribution channel influences commercialization plans; offline sales through direct sales teams or distributors enable clinician-focused engagement and training, whereas online sales can accelerate consumer-directed access for select device classes and peripheral supplies.

Technological wear paradigms-continuous wear versus intermittent wear-shape patient experience and device architecture. Continuous wear options demand extended-duration materials and power solutions, whereas intermittent use models focus on shorter duration reliability and ease of donning and doffing. Age group segmentation between adult and pediatric populations introduces differing ergonomic and dosing considerations and often necessitates tailored clinical trial design and regulatory strategies. Each of these segment axes interacts dynamically, informing product roadmaps, support infrastructure, and commercial models.

A regional comparative perspective on healthcare infrastructure, reimbursement realities, regulatory diversity, and commercialization pathways across global markets

Geographic dynamics vary significantly across major regions, with differences in healthcare infrastructure, payer systems, and regulatory frameworks shaping development and adoption pathways. In the Americas, established clinical networks and advancing outpatient care models are creating demand for ambulatory and home-based renal solutions, with a focus on integrated care delivery and reimbursement clarity. Providers in this region often prioritize devices that demonstrate clear outcomes and operational efficiencies that can be integrated into existing dialysis networks.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse healthcare funding models create both opportunities and complexities. High-income markets within this region are receptive to innovative device classes when supported by robust clinical evidence and pathway alignment, while emerging markets emphasize cost-effectiveness and supply chain accessibility. Here, strategic partnerships with regional distributors and adaptive pricing models can be decisive for adoption and scale.

Asia-Pacific presents a mix of mature and rapidly evolving markets where urbanization, rising chronic disease burden, and investment in digital health infrastructure are driving interest in wearable renal technologies. Regulatory modernization in some jurisdictions and active medical device ecosystems encourage local innovation and trial activity. Across these regional dynamics, manufacturers must calibrate clinical development plans, regulatory strategies, and commercial models to the distinct reimbursement expectations and care delivery realities in each geography.

A strategic distillation of competitive dynamics, partnership models, intellectual property focus, and investment priorities shaping wearable artificial kidney industry leadership

The competitive landscape combines legacy dialysis manufacturers, medtech incumbents, and agile startups focused on novel sorbent chemistry, lightweight fluidics, and integrated sensing. Legacy firms contribute deep clinical relationships, manufacturing scale, and established distribution networks that can accelerate market entry for new device classes when coupled with iterative clinical validation. Startups and spinouts, often originating from academic engineering or clinical research groups, bring rapid prototyping, user-centered design, and a willingness to pursue unconventional regulatory and reimbursement strategies.

Partnership models are increasingly prevalent; collaborations between device innovators and larger medical device firms, contract manufacturers, or clinical research organizations allow for pooled expertise across clinical development, regulatory navigation, and manufacturing scale-up. Intellectual property landscapes are competitive, with strong emphasis on proprietary sorbent formulations, membrane technologies, and integrated sensor algorithms. Contract manufacturing organizations and specialized component suppliers play a pivotal role in enabling scale while preserving design flexibility.

Investors and strategic acquirers are seeking evidence of clinical differentiation, regulatory progress, and a credible path to manufacturing quality systems. Firms that combine demonstrable clinical benefit, a clear regulatory pathway, and scalable manufacturing partnerships will be most attractive as collaborators or acquisition targets. Ultimately, the ecosystem rewards those that can marry clinical rigor with operational readiness and a compelling patient experience.

A pragmatic set of actionable strategies for clinical validation, supply chain diversification, regulatory engagement, manufacturing scale-up, and payer collaboration to accelerate adoption

Industry leaders should pursue a multi-pronged strategy that balances clinical validation, supply chain resilience, and commercial readiness to accelerate adoption while mitigating risk. Prioritize rigorous, patient-centric clinical programs that address both traditional endpoints and quality-of-life measures; integrating patient-reported outcomes into early studies will strengthen value communication to payers and providers. Simultaneously, engage regulatory authorities early to align on acceptable safety and performance endpoints and to explore adaptive pathways that can streamline market access.

From an operational perspective, diversify component sourcing and evaluate regional manufacturing options to reduce exposure to trade policy shifts and component shortages. Invest in quality systems and scalable manufacturing partnerships that can transition prototypes into production while meeting international device standards. On the commercial front, develop differentiated value propositions for ambulatory centers, home care programs, and hospital clinics, and deploy tailored training and remote-monitoring services that reduce clinician burden and enhance adherence.

Finally, build collaborative relationships with payers and healthcare systems to pilot reimbursement models that reflect total-cost-of-care benefits. Consider strategic alliances or licensing agreements with established device manufacturers to leverage distribution networks, or pursue targeted acquisitions to acquire critical technologies or manufacturing capacity. These actions, taken in combination, create a defensible path to sustainable market entry.

A transparent explanation of the mixed-methods research approach combining primary interviews, clinical literature synthesis, regulatory review, IP landscaping, and supply chain mapping used to derive insights

The research underpinning these insights relied on a mixed-methods approach that triangulated primary stakeholder interviews, clinical literature synthesis, regulatory document review, and supply chain analysis. Primary research included in-depth interviews with nephrology clinicians, biomedical engineers, hospital procurement leaders, and device development executives to capture real-world operational and clinical priorities. These qualitative inputs were supplemented by systematic reviews of peer-reviewed clinical trials, investigator-led studies, and device registries to assess safety signals and efficacy endpoints.

Regulatory landscapes were analyzed through careful review of guidance documents, approval pathways, and public filings in major jurisdictions. Patent and intellectual property landscaping provided perspective on technology trajectories and areas of competitive advantage. Supply chain mapping combined publicly available trade data with industry interview insights to identify critical components, manufacturing bottlenecks, and potential tariff exposure points.

All findings were validated through cross-referencing multiple independent sources and through iterative expert review sessions. Where gaps existed, targeted follow-up interviews and technical consultations were conducted to ensure that recommendations reflect both clinical realities and operational feasibility. This methodological rigor supports actionable guidance while acknowledging areas where further clinical evidence or regulatory clarity is required.

A conclusive synthesis highlighting the interdependent imperatives of clinical validation, regulatory alignment, supply chain resilience, and stakeholder value for scaling wearable renal solutions

Wearable artificial kidney technologies inhabit a pivotal intersection of unmet clinical need, accelerating technological capability, and evolving healthcare delivery models. The pathway to broad clinical adoption depends not only on engineering performance but also on rigorous clinical validation, aligned regulatory strategies, resilient supply chains, and clear reimbursement pathways. Manufacturers that successfully integrate patient-centered design with demonstrable clinical outcomes and operational scalability will be best positioned to influence care paradigms.

Stakeholder alignment is essential: clinicians need robust evidence and predictable workflows, payers require cost-effectiveness and outcome improvements, and patients expect safety, comfort, and meaningful gains in daily life. Strategic decisions around sourcing, manufacturing localization, and commercial partnerships will shape which innovations achieve scale. Policy developments and trade dynamics add complexity but also create opportunities for reshaping supply chains in favor of resilience and near-term stability.

In closing, the wearable artificial kidney sector is transitioning from exploratory prototypes toward practical, scalable solutions. The organizations that prioritize clinical rigor, anticipate policy and supply chain shifts, and craft compelling value propositions for diverse care settings will define the next phase of renal replacement therapy innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Wearable Artificial Kidney Market, by Therapy Type

  • 8.1. Hemodialysis
    • 8.1.1. Conventional Hemodialysis
    • 8.1.2. Ultraportable Hemodialysis
  • 8.2. Peritoneal Dialysis
    • 8.2.1. Automated Peritoneal Dialysis
    • 8.2.2. Continuous Ambulatory Peritoneal Dialysis

9. Wearable Artificial Kidney Market, by Technology

  • 9.1. Continuous Wear
    • 9.1.1. Extended Duration
    • 9.1.2. Short Duration
  • 9.2. Intermittent Wear
    • 9.2.1. Daily Use
    • 9.2.2. Periodic Use

10. Wearable Artificial Kidney Market, by Age Group

  • 10.1. Adult
  • 10.2. Pediatric

11. Wearable Artificial Kidney Market, by End User

  • 11.1. Ambulatory Center
  • 11.2. Home Care
  • 11.3. Hospital Clinic

12. Wearable Artificial Kidney Market, by Distribution Channel

  • 12.1. Offline Sales
    • 12.1.1. Direct Sales
    • 12.1.2. Distributor
  • 12.2. Online Sales

13. Wearable Artificial Kidney Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Wearable Artificial Kidney Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Wearable Artificial Kidney Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Wearable Artificial Kidney Market

17. China Wearable Artificial Kidney Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ANSELL LTD
  • 18.6. Asahi Kasei Medical Co., Ltd.
  • 18.7. Awak Technologies
  • 18.8. B. Braun Melsungen AG
  • 18.9. Baxter International Inc.
  • 18.10. Cardinal Health
  • 18.11. Dynarex Corporation
  • 18.12. GE Healthcare
  • 18.13. Hartalega Holdings
  • 18.14. Hitachi Medical Corporation
  • 18.15. KAWASUMI LABORATORIES, INC
  • 18.16. Koninklijke Philips N.V.
  • 18.17. Medline Industries, Inc
  • 18.18. Nanodialysis BV
  • 18.19. Siemens AG
  • 18.20. Triomed AB
  • 18.21. Wearable Artificial Organs Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONVENTIONAL HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONVENTIONAL HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONVENTIONAL HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ULTRAPORTABLE HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ULTRAPORTABLE HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ULTRAPORTABLE HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AUTOMATED PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AUTOMATED PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AUTOMATED PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY EXTENDED DURATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY EXTENDED DURATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY EXTENDED DURATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY SHORT DURATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY SHORT DURATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY SHORT DURATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DAILY USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DAILY USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DAILY USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERIODIC USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERIODIC USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERIODIC USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AMBULATORY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AMBULATORY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AMBULATORY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HOSPITAL CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HOSPITAL CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HOSPITAL CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 182. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 183. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 215. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 216. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 226. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 227. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY CONTINUOUS WEAR, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY INTERMITTENT WEAR, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA WEARABLE ARTIFICIAL KIDNEY MARKET SIZE, BY OFFLINE SALES, 2018-2032 (USD MILLION)